REGENXBIO Inc. $RGNX Position Increased by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in REGENXBIO Inc. by 52.4%, acquiring an additional 27,341 shares, bringing its total ownership to 79,469 shares valued at approximately $568,000.
• Institutional investors own 88.08% of REGENXBIO, with significant increases in holdings from firms like Millennium Management and Vanguard Group during recent quarters.
• REGENXBIO reported a quarterly earnings loss of ($1.38) per share, missing the consensus estimate, and had revenue of $21.36 million, below expectations of $40.87 million.

Invesco Ltd. raised its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 52.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,469 shares of the biotechnology company's stock after acquiring an additional 27,341 shares during the period. Invesco Ltd. owned approximately 0.16% of REGENXBIO worth $568,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC bought a new stake in shares of REGENXBIO in the first quarter worth $484,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of REGENXBIO during the 1st quarter valued at approximately $123,000. Price T Rowe Associates Inc. MD boosted its holdings in REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after buying an additional 1,982 shares during the period. BNP Paribas Financial Markets boosted its holdings in REGENXBIO by 370.1% in the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after purchasing an additional 75,652 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of REGENXBIO during the 4th quarter valued at $568,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Trading Up 3.1%

RGNX traded up $0.29 on Friday, hitting $9.71. 609,824 shares of the company were exchanged, compared to its average volume of 643,702. REGENXBIO Inc. has a twelve month low of $5.03 and a twelve month high of $13.48. The company has a market cap of $490.45 million, a price-to-earnings ratio of -2.82 and a beta of 1.17. The firm has a 50-day moving average price of $8.65 and a two-hundred day moving average price of $8.18.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The business had revenue of $21.36 million for the quarter, compared to analysts' expectations of $40.87 million. Equities analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.

Wall Street Analysts Forecast Growth

RGNX has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of REGENXBIO in a research note on Tuesday, August 19th. Barclays lowered their target price on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Royal Bank Of Canada dropped their target price on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Wall Street Zen cut REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Finally, Chardan Capital reiterated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, REGENXBIO currently has a consensus rating of "Moderate Buy" and an average price target of $28.38.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.